High frequency of latent membrane protein-1 30-bp deletion variant with specific single mutations in Epstein-Barr virus-associated nasopharyngeal carcinoma in Moroccan patients

International Journal of Cancer

Volumn 118, Issue 8, 2006, Pages 1977-1983

  Dardari, Rkia ^a,b   Khyatti, Meriem ^b   Cordeiro, Paulo ^a   Odda, Mohieddine ^c   ElGueddari, Brahim ^c   Hassar, Mohammad ^b   Menezes, José ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b Institut Pasteur du Maroc   (Morocco)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

Author keywords

Epstein Barr virus; LMP 1 variants; Moroccan patients; Nasopharyngeal carcinoma

Indexed keywords

LATENT MEMBRANE PROTEIN 1; ONCOPROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENDEMIC DISEASE; EPSTEIN BARR VIRUS; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOROCCO; NASOPHARYNX CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; PROTEIN VARIANT;

BASE SEQUENCE; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; EPSTEIN-BARR VIRUS INFECTIONS; GEOGRAPHY; HERPESVIRUS 4, HUMAN; HUMANS; MOLECULAR SEQUENCE DATA; MOROCCO; NASOPHARYNGEAL NEOPLASMS; VARIATION (GENETICS); VIRAL MATRIX PROTEINS; VIROLOGY;

EID: 33645231702     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21595     Document Type: Article

References (41)

1. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 1968;59:94-101.
2. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fileds BN, Knipe DM, Howley PM, eds.Fields virology, 3rd ed, vol. 2. Philadelphia: Lippincott-Raven, 1996.2397p.
3. Knecht H, Berger C, al-Homsi AS, McQuain C, Brousset P. Epstein-Barr virus oncogenesis. Crit Rev Oncol Hematol 1997;26(2):117-35.
4. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds.Cancer incidence in five continents, vol. VII, IARC Scientific Publications No. 143. Lyon: IARC, 1997.
5. Benider A, Sahraoui S, Acharki A, Samlali R, Kahlain A. Carcinomas of the nasopharynx in children. Analysis of 50 cases. Bull Cancer 1995;82(2):155-61.
6. Chaouki N, el Gueddari B. Epidemiological descriptive approach of cancer in Morocco through the activity of the National Institute of Oncology. 1986-1987. Bull Cancer 1991;78:603-9.
7. Chen F, Hu LF, Ernberg I, Klein G, Winberg G. Coupled transcription of Epstein-Barr virus latent membrane protein (LMP)-1 and LMP-2B genes in nasopharyngeal carcinomas. J Gen Virol 1995;76:131-8.
8. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43(3 Part 2):831-40.
9. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990;344:777-80.
10. Yoshizaki T, Sato H, Furukawa M, Pagano JS. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci USA 1998;95:3621-6.
11. Lu J, Chua HH, Chen SY, Chen JY, Tsai CH. Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 2003;63:256-62.
12. Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995;69:4390-8.
13. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, Pagano JS. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001;98:6905-10.
14. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
15. Wang S, Rowe M, Lundgren E. Expression of the Epstein-Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 1996;56:4610-3.
16. Gregory CD, Murray RJ, Edwards CF, Rickinson AB. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med 1988;167:1811-24.
17. Rowe M, Peng-Pilon M, Huen DS, Hardy R, Croom-Carter D, Lundgren E, Rickinson AB. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-κ B activation and to induction of cell surface markers. J Virol 1994;68:5602-12.
18. Paine E, Scheinman RI, Baldwin AS, Jr, Raab-Traub N. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-κ B/Rel family proteins. J Virol 1995;69:4572-6.
19. Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E. Role of the TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998;72:7900-8.
20. Miller WE, Mosialos G, Kieff E, Raab-Traub N. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. J Virol 1997;71:586-94.
21. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA 1997;94:1447-52.
22. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 1999;274:16085-96.
23. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. Embo J 1997;16:6478-85.
24. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κ B. J Biol Chem 1992;267:24157-60.
25. Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, Zeidler R. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. Embo J 1999;18:3064-73.
26. Blake SM, Eliopoulos AG, Dawson CW, Young LS. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology 2001;282:278-87.
27. Chen ML, Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D, Liu ST, Chang YS. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 1992;7:2131-40.
28. Li SN, Chang YS, Liu ST. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 1996;12:2129-35.
29. Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology 1999;261:79-95.
30. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, Wingberg G. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 1991;72(Part 10):2399-409.
31. Bouzid M, Djennaoui D, Dubreuil J, Bouguermouh A, Ellouz D, Abdelwahab J, Decaussin G, Ooka T. Epstein-Barr virus genotypes in NPC biopsies from north Africa. Int J Cancer 1994;56:468-73.
32. Grunewald V, Bonnet M, Boutiri S, Yip T, Louzir H, Levrero M, Seigneurin JM, Raphael M, Touitou R, Martel-Renoir D, Cochet C, Durandy A, et al. Amino-acid change in the Epstein-Barr-virus ZEBRA protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa. Int J Cancer 1998;75:497-503.
33. Edwards RH, Sitki-Green D, Moore DT, Raab-Traub N. Potential selection of LMP1 variants in nasopharyngeal carcinoma. J Virol 2004;78:868-81.
34. Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, De Carli M, Fiaccadori F, Ferrari C. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994;369:407-10.
35. Burrows JM, Burrows SR, Poulsen LM, Sculley TB, Moss DJ, Khanna R. Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J Virol 1996;70:2490-6.
36. Dardari R, Khyatti M, Jouhadi H, Benider A, Ettayebi H, Kahlain A, Mansouri A, El Gueddari B, Benslimane A. Study of human leukocyte antigen class I phenotypes in Moroccan patients with nasopharyngeal carcinoma. Int J Cancer 2001;92(2):294-7.
37. Liu Y, Wang X, Lo AK, Wong YC, Cheung AL, Tsao SW. Latent membrane protein-1 of Epstein-Barr virus inhibits cell growth and induces sensitivity to cisplatin in nasopharyngeal carcinoma cells. J Med Virol 2002;66:63-9.
38. Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, Wong N, Yuen PW, Lo AK, Wong YC, Huang DP. Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta 2002;1590(1-3):150-8.
39. Brennan P, Floettmann JE, Mehl A, Jones M, Rowe M. Mechanism of action of a novel latent membrane protein-1 dominant negative. J Biol Chem 2001;276:1195-203.
40. Chen H, Lee JM, Zong Y, Borowitz M, Ng MH, Ambinder RF, Hyaward SD. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol 2001;75:2929-37.
41. Moorthy RK, Thorley-Lawson DA. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol 1993;67:1638-46.